Our recently published clinical trial demonstrated promising therapeutic responses in elderly AML patients or ineligible for IC treated with Aza combined with HAG (HHT, low-dose cytarabine, G-CSF) (23). This evidence concerns the gene CSF3 and acute myeloid leukemia.